Noxopharm Ltd has released a press release.
Veyonda Survival Advantage in LuPSMA Therapy Confirmed
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- June 2021 Quarterly Activities Report and Appendix 4C
- DARRT-2 Study Receives IND Approval from FDA
- Noxopharm Secures Key European Patent Allowance for Veyonda
- DARRT-2 Study Update and Clarification
- Noxopharm Set to Benefit From Novartis ASCO Data
Later from Noxopharm
- NOX and US Govt Peak Cancer Agency Announce Collaboration
- Noxopharm: Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer
- NOXCOVID Program to Expand After Positive Phase 1 Results
- Pre-clinical Data Supports a Role for Veyonda in COVID-19
- Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm